Do current parathyroid hormone immunoassays adequately meet the needs of patients with chronic kidney disease?
Existing between-method differences in PTH measurements clearly have treatment implications. International initiatives to address these differences are in progress and will require support and input from all stakeholders. Adoption of assay-specific target values such as those reported here provides a convenient and practical interim solution that should lead to significant improvement in patient management, while also enabling meaningful audit.
Polymorphism of the beta1-adrenoceptor gene influences long-term weight gain and the incidence of adult-onset overweight in women.